The immune profiling analysis of peripheral blood reveals an increased abundance of LAG-3PD-1 memory CD4T cell subset in relapsed cholangiocarcinoma patients after gemcitabine plus cisplatin therapy, which are more responsive to ABL501. This study supports the clinical evaluation of ABL501 as a novel cancer immunotherapeutic, and a first-in-human trial has started (NCT05101109).

almost 2 years ago

Journal

CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)

cisplatin • gemcitabine • ABL501

3years

[VIRTUAL] ABL501, PD-L1 x LAG-3, a bispecific antibody promotes enhanced human T cell activation through targeting simultaneously two immune checkpoint inhibitors, LAG-3 and PD-L1 (AACR 2021)

Together with safety profile in the toxicology study, the preclinical studies support that ABL501 effectively suppressed tumor growth through activation of immune cells by releasing immune suppressive environments. This alternative therapeutic strategy may have a potential to overcome limitations of the current immune-oncology therapy for further clinical evaluation.

3 years ago

Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker

LAG3 (Lymphocyte Activating 3)

LAG3 expression

ABL501